Počet záznamů: 1
Evaluation of 177Lu-nimotuzumab for Targeted Radioimmunotherapy of EGFR Expressing Tumors
- 1.
SYSNO ASEP 0385312 Druh ASEP A - Abstrakt Zařazení RIV Záznam nebyl označen do RIV Zařazení RIV Není vybrán druh dokumentu Název Evaluation of 177Lu-nimotuzumab for Targeted Radioimmunotherapy of EGFR Expressing Tumors Tvůrce(i) Beckford, Denis R. (UJF-V) RID
Balogh, L. (HU)
Postenyi, Z. (HU)
Mathe, D. (HU)
Eigner, Sebastian (UJF-V) RID
Eigner-Henke, Kateřina (UJF-V) RID
Montana, R. L. (CU)
Melichar, František (UJF-V) RIDCelkový počet autorů 8 Zdroj.dok. European Journal of Nuclear Medicine and Molecular Imaging. - : Springer - ISSN 1619-7070
Roč. 39, P0089 (2012), S327-S327Poč.str. 1 s. Akce 25th Annual Congress of the European-Association-of-Nucelar Medicine Datum konání 27.10.2012-31.10.2012 Místo konání Milan Země IT - Itálie Typ akce EUR Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova radiotherapy ; tumor treatment Vědní obor RIV BG - Jaderná, atomová a mol. fyzika, urychlovače Institucionální podpora UJF-V - RVO:61389005 Anotace Nimotuzumab radiolabeled with 99mTc and 188Re has been successfully used for imaging and therapy of EGFR overexpressing tumors in clinical trials. 177Lu is being strongly considered for radioimmunotherapy due to its excellent nuclear properties and suitability for imaging and dosimetry determination. Therefore, the aim of this work was to evaluate the therapeutic effect of 177Lu-nimotuzumab in a tumor animal model. Methods: Nimotuzumab was modified with p-SCN-Bn-DOTA and radiolabeled with n. c. a. 177Lu. The radioimmunoconjugate was characterized by size exclusion radio-HPLC. Specificity and affinity were tested using radioimmunoassays in a cell line overexpressing EGFR. Radioimmunotherapy study was performed in BALB/c-nu mice bearing human A431 and MCF-7 xenografts. Mice were divided in four groups and 177Lu-nimotuzumab (15 - 45 MBq/mouse) was intravenously administered. The effect in tumor growth and survival after single injection of 177Lu-nimotuzumab was studied. In addition, the ratio in tumor uptake between A431 and MCF-7 tumors was also studied. Results: Radiochemical yield and specific activity of 177Lu-Nimotuzumab were higher than 95% and 1.3 GBq/mg, respectively. The binding of 177Lu-nimotuzumab to A431 cells showed to be EGFR specific. A single dose of 177Lu-nimotuzumab (15 - 45 MBq/mouse) reduces tumor growth in A431 and MCF-7 tumors after 3 weeks of treatment. Tumor volume was 3.7 to 4.3 times higher in MCF-7 tumors than in A431 xenografts after 6 weeks of treatment. The tumor uptake of 177Lu-nimotuzumab in A431 tumors was 1.4 to 2.1 times higher than in MCF-7 tumors. The survivals were statistically different among the groups. No death occurred in the group treated with 15 MBq of 177Lu-nimotuzumab. Conclusions: The results showed the therapeutic effect of 177Lu-nimotuzumab to be potential for radioimmunotherapy of EGFR overexpressing tumors. Pracoviště Ústav jaderné fyziky Kontakt Markéta Sommerová, sommerova@ujf.cas.cz, Tel.: 266 173 228 Rok sběru 2013
Počet záznamů: 1